A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 244
- Population
- ALL · 50 Years
- Duration
- 2026-09-01 to 2028-10-01
- Intervention
- VIS-101 6.0mg Low concentration; VIS-101 6.0mg High concentration; VIS-101 9.0mg High concentration; Aflibercept (Eylea)
- Comparator
- Aflibercept
- Outcomes measured
- Change in BCVA from baseline to average of Weeks 20, 24, and 28 — From Baseline through Week 28; Change in BCVA from baseline — Throughout week 48; Dosing interval — Throughout week 48; Number of injections — Throughout week 44; Change in CST from baseline — Throughout week 28 and week 48; Proportion of participants with no intraretinal fluid — Throughout week48; Proportion of participants with no subretinal fluid — Throughout week48; Proportion of participants with no intraretinal and subretinal fluid — Throughout week48; Proportion of participants with no intraretinal cysts — Throughout week48; Proportion of participants with no retinal pigment epithelial (RPE) detachment — Throughout week48; Change in total area of CNV lesion from baseline — Throughout week 28 and 48; Change in total leakage area from baseline — Throughout week 28 and 48; Incidence and severity of post-treatment adverse events, treatment-related adverse events and serious adverse events —…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.